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The prevalence of end-stage renal disease (ESRD) and the number of kidney transplants 
performed continues to rise every year, straining the procurement of deceased and 
living kidney allografts and health systems. Genome-wide genotyping and sequencing 
of diseased populations have uncovered genetic contributors in substantial proportions 
of ESRD patients. A number of these discoveries are beginning to be utilized in risk 
stratification and clinical management of patients. Specifically, genetics can provide 
insight into the primary cause of chronic kidney disease (CKD), the risk of progression to 
ESRD, and post-transplant outcomes, including various forms of allograft rejection. The 
International Genetics & Translational Research in Transplantation Network (iGeneTRAiN), 
is a multi-site consortium that encompasses >45 genetic studies with genome-wide 
genotyping from over 51,000 transplant samples, including genome-wide data from >30 
kidney transplant cohorts (n = 28,015). iGeneTRAiN is statistically powered to capture 
both rare and common genetic contributions to ESRD and post-transplant outcomes. 
The primary cause of ESRD is often difficult to ascertain, especially where formal biopsy 
diagnosis is not performed, and is unavailable in ~2% to >20% of kidney transplant 
recipients in iGeneTRAiN studies. We overview our current copy number variant (CNV) 
screening approaches from genome-wide genotyping datasets in iGeneTRAiN, in attempts 
to discover and validate genetic contributors to CKD and ESRD. Greater aggregation and 
analyses of well phenotyped patients with genome-wide datasets will undoubtedly yield 
insights into the underlying pathophysiological mechanisms of CKD, leading the way to 
improved diagnostic precision in nephrology.
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INTRODUCTION
The global prevalence of end-stage renal disease (ESRD) 
continues to climb. In 2016, 19,301 kidney transplants were 
performed in the United States, and approximately five times 
as many were performed worldwide1,2. Due to improvements in 
surgical techniques, immunosuppression protocols, and clinical 
management of post-transplant complications, the five-year graft 
survival rates for kidneys obtained from deceased and living 
donors reached highs of 75.3% and 85.3%, respectively (Cohen 
et al.,2006; Serur et al., 2011; Vignolini et al., 2019). However, 
the prevalence of ESRD cases in the US has continued to rise by 
~20,000 cases per year over the past three decades, creating an 
increased need for kidney allografts1. This increase is believed to 
be due primarily to worsening diets and other modifiable factors 
associated with Western lifestyle but also to an increase in the 
longevity of pre-transplant ESRD cases.
It is well established that genetic factors contribute to the 
development and progression of specific types of chronic 
kidney disease (CKD), yet many previous studies have been 
limited in scope due to small sample sizes and genotyping 
strategies (Azarpira et al., 2014; Misra et al., 2014;  Phelan 
et al 2014; Parsa et al., 2017; Stapleton et al., 2018). Studies of 
families with severe phenotypes of diseases, such as Alport’s 
Syndrome and Fabry Disease, have significantly contributed 
to the understanding of the genetic characteristics of these 
conditions (Gillion et al., 2018; Kashiwagi et al., 2018; 
McCloskey et al., 2018). However, milder forms of these 
diseases and their role in the development of ESRD have yet to 
be explored in great depth.
Genome-Wide Genotyping Arrays
Array based genome-wide genotyping from diverse patient 
populations facilitates very precise ancestry determination using 
methods such as principal component analysis (Cai et al., 2013; 
Li et al., 2015). Genome-wide association studies (GWAS) among 
patients with CKD have detected both rare and common genetic 
variants significantly associated with estimated glomerular 
filtration rate (eGFR) decline and microalbuminuria, some of the 
strongest predictors of CKD outcomes, despite >80% of GWAS 
participants having eGFRs in the normal range (Boger et al., 
2011a; Boger et al., 2011b;Reznichenko et al., 2012; Gorski et al., 
2015; Parsa et al., 2017; Limou et al., 2018).
The findings of genome-wide studies may also provide new 
therapeutic targets to slow the progression of CKD to ESRD, 
which may delay or impact the need for transplantation in some 
patient populations (Wuttke & Kottgen, 2016; Kalatharan et al., 
2018). For example, nephropathic cystinosis, a rare autosomal 
recessive disease, is caused by a 57-kb deletion in the CTNS gene 
in ∼75% of patients of European ancestry and progresses to 
ESRD if left untreated (Brodin-Sartorius et al., 2012). However, 
treatment with oral cysteamine by five years of age has been 
found to significantly decrease the prevalence and delay the onset 
1 https://www.usrds.org
2 http://www.transplant-observatory.org
of ESRD (Brodin-Sartorius et al., 2012). Additionally, at least 38 
genes have been associated with the development of genetic focal 
segmental glomerulosclerosis (FSGS), some of which have been 
shown to be responsive to glucocorticoid treatment (Rosenberg 
& Kopp, 2017). GWAS findings can also provide insight into the 
biology of ESRD, helping to remove diagnostic heterogeneity. 
The two APOL1 risk alleles (G1 and G2) found in high frequency 
in sub-Saharan African populations and strongly associated 
with FSGS and HIV nephropathy were found to activate protein 
kinase R, thus inducing glomerular injury and proteinuria (Kopp 
et al., 2011; Limou et al., 2014; Okamoto et al., 2018). Overall, 
results from genome-wide screening can enable physicians to 
provide accurate genetic diagnoses for the primary cause of 
ESRD, enabling timely and effective therapeutic managemenvwt 
and aiding in the evaluation of family members as living donors 
(Snoek et al., 2018).
Whole-Exome and Whole-Genome Sequencing
In the last decade, whole-exome sequencing (WES) and whole-
genome sequencing (WGS) approaches have been used very 
successfully to discover and diagnose genetic disorders in a 
clinical context (Mallawaarachchi et al., 2016; Lata et al., 2018; 
Warejko et al., 2018; Groopman et al., 2019). WES typically 
yields sufficient depth of sequencing coverage across ~95% of 
nucleotides in coding regions captured and has been used to 
diagnose rare high penetrant, Mendelian disorders, discover 
common variants, and identify causal mutations in cancer 
(Huang et al., 2018; Zhang et al., 2018). WES has recently been 
implemented as a first-line diagnostic tool in clinical medicine. 
In a study on fetuses with congenital anomalies of the kidney and 
urinary tract (CAKUT), pathogenic variants were discovered in 
13% of cases (Lei et al., 2017). WES has also been applied to 
adult-onset CKD and ESRD, in which ~10% of cases are caused 
by Mendelian mutations (Wuhl et al., 2014; Lata et al., 2018; 
Groopman et al., 2019). In a cohort of >3,000 patients with 
advanced CKD and ESRD ascertained for a clinical trial, WES 
identified diagnostic variants in 9.3% of patients encompassing 
66 monogenic disorders (Groopman et al., 2019). Of the 343 
detected variants, 141 (41%) had not been previously reported 
as pathogenic. Additionally, diagnostic variants were identified 
in 17.1% of individuals with nephropathy of unknown origin, 
altering medical management by initiating multidisciplinary 
care, prompting referral to clinical trials, and guiding donor 
selection for transplantation (Groopman et al., 2019). 
However, it should be noted that many CKD studies using 
WES have struggled to obtain adequate control populations. 
iGeneTRAiN has a large pool of healthy donors (in kidney and 
in other organs), which represents a strong advantage for our 
study designs.
WGS is the most comprehensive approach for the detection 
of inherited variants due to more complete genome-wide 
coverage, although there are additional challenges compared 
to WES. WGS can capture single nucleotide genetic variants, 
small Insertions and Deletions (Indels), and Copy-Number 
Variants (Cnvs) throughout the human genome. Although 
it has a higher cost per sample and can be more difficult to 
analyze than wes, greater diagnostic yields are evident in 
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patients with negative or inconclusive wes results (Alfares et al., 
2018; Lionel et al., 2018). WGS has been shown to identify a 
diagnostic genetic variant in ~10–50% of individuals with a 
suspected genetic disorder, depending on the clinical study 
population(S-) being screened (van Der Ven et al., 2018; 
Groopman et al., 2019; Mann et al., 2019).
International Genetics and Translational Research in 
Transplantation Network
Despite technological advances that enable research to be 
carried out on a genome-wide scale, many studies have been 
hindered by small sample sizes in single transplant sites, 
as well as the vast number of complex donor and recipient 
clinical covariates and disease-related phenotypes observed 
in transplantation. The International Genetics & Translational 
Research in Transplantation Network (iGeneTRAiN) is a 
multi-site consortium that encompasses >45 genetic studies 
with ~51,210 solid-organ transplant subjects (International 
Genetics and Translational Research in Transplantation Network 
(iGeneTRAiN), 2015). The iGeneTRAiN consortium aims to 
discover and validate solid organ transplant related genetic factors 
and post-transplant complications, including primary disease, 
disease recurrence, drug- and cardio-metabolic related adverse 
events, and different forms of allograft rejection (International 
Genetics and Translational Research in Transplantation Network 
(iGeneTRAiN), 2015). Of the iGeneTRAiN samples, 54% (n = 
28,015) are from kidney transplant cohorts and include 17,742 
(63.3%) recipients and 10,273 (36.7%) donors. The genotyped 
donor DNA provides control samples for all iGeneTRAiN studies, 
a large advantage over previously published genetic studies.
The iGeneTRAiN consortium designed and developed 
a genome-wide genotyping array, the “TxArray,” which was 
enriched with content relating to known or putative transplant-
specific genetic associations (Li et al., 2015). The TxArray version 
1 contains ~782,000 genetic markers, with tailored transplant-
specific content to capture variants across HLA, KIR, loss-of-
function, pharmacogenomic, and cardio-metabolic loci. The 
array also contains extensive overlap with the UK Biobank 
Axiom® Array and the Axiom Biobank Genotyping Array, 
enabling future joint studies or meta-analyses using conventional, 
hypothesis-free GWAS approaches (Li et al., 2015).
The first wave of iGeneTRAiN kidney cohorts had a wide 
geographic representation with participants from various sites 
in the United States, Canada, Australia, The Netherlands, United 
Kingdom, and Ireland, including both adult and pediatric sites 
(Figure 1). Over the past few years, many genetic discoveries 
have been made within the iGeneTRAiN cohorts related to 
kidney, heart, liver, and lung transplants (Oetting et al., 2016; 
Greenland et al., 2017; Shaked et al., 2017; Hernandez-Fuentes 
et al., 2018; Oetting et al., 2018; Snoek et al., 2018; Oetting et 
al., 2019; Reindl-Schwaighofer et al., 2019). The Wellcome Trust 
Case Control Consortium (WTCCC) carried out the first large-
scale GWAS with both kidney transplant donor and recipient 
DNA with the goal of identifying genetic variants, in addition 
to the HLA regions, that significantly contribute to long- and/
or short-term renal allograft survival (Hernandez-Fuentes 
FIGURe 1 | Geographical Map of Current iGeneTRAiN Kidney Sites and Sub-sites.
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et al., 2018). No non-HLA signals were observed at genome-
wide significance in this initial study, illustrating the need for 
harmonization of larger, well-phenotyped kidney transplant 
cohorts. In addition to the previously discovered common 
loss-of-function variant CYP3A5*3 allele (rs776746), the 
Deterioration of Kidney Allograft Function (DeKAF) Trial 
identified two CYP3A5 variants, rs10264272 and rs41303343, 
and one CYP3A4 variant, rs35599367, that explain additional 
portions of variance observed in dose-adjusted tacrolimus 
(TAC) through blood concentrations for African American 
(AA) and European ancestry (EA) kidney transplant recipients, 
respectively (Dai et al., 2006; Jacobson et al., 2011; Oetting et al., 
2016; Oetting et al., 2018). These findings illustrate the utility of 
genome-wide studies when determining immunosuppression 
therapy regimens post-transplant, potentially contributing to 
improvements in renal allograft survival. Another iGeneTRAiN 
study showed that GWAS performed in nontransplant settings 
can predict post-transplant complications. Polygenic risk scores 
calculated from non-melanoma skin cancer (NMSC) GWAS 
in the general population predicted risk of and time to post-
transplant NMSC and added additional predictive value beyond 
that explained by clinical variables (Stapleton et al., 2019).
Ongoing iGeneTRAiN Kidney Genome-Wide Studies
Recently, additional kidney transplant cohorts from Austria, 
Belgium, Germany, France, Italy, The Netherlands, Saudi 
Arabia, South Korea, Switzerland, and additional United States 
sites have joined iGeneTRAiN. This greatly increases ancestral 
diversity of recipients and donors, as well as statistical power to 
detect transplant related genetic variants that impact primary 
disease and transplant outcomes (Figure 1). Our large sample 
sizes are enabling us to investigate both donor and recipient 
characteristics that effect ESRD cause, treatment, and transplant-
related outcomes.
Where available, we obtained formal clinical diagnoses 
of primary cause of ESRD, organized into disease categories 
of diabetic, arteriopathic, glomerular, acute kidney injury, 
infective and obstructive nephropathy, congenital, familial, toxic 
nephropathy, and malignancies, for all iGeneTRAiN kidney 
cohort subjects (Table 1). With these datasets, we are working 
to increase our understanding of the genetic underpinnings 
of ESRD and primary disease through single nucleotide 
polymorphism (SNP) based GWAS, copy number variant 
(CNV) screening, donor-recipient properties, allogenicity, and 
transplant outcomes.
Copy Number variant Screening in 
iGeneTRAiN  Cohorts
Genome-wide genotyping arrays are well established as an 
effective means for identification of known and novel CNVs 
(Sallustio et al., 2015; Ai et al., 2016; Verbitsky et al., 2019). CNV 
screening within iGeneTRAiN subjects is of major interest for 
both assessing the genetic architecture of primary disease and 
for allogenicity studies. iGeneTRAiN has developed an extensive 
loss-of-function (LoF) pipeline which includes haplotype phasing 
of over 10 million directly genotyped and imputed variants. We 
are particularly interested in two copy LoF (by single-nucleotide 
variants and/or CNVs) and integration of one or two copy LoF 
variants for donor-recipient interaction analyses, for association 
with time-to-rejection and graft loss events (International 
Genetics and Translational Research in Transplantation Network 
(iGeneTRAiN), 2015).
CNV screening in a priori regions for primary disease has been 
performed in iGeneTRAiN cohorts. For example, we performed 
CNV screening in patients with nephronophthisis (NPH), the 
most common genetic cause of ESRD in children and often 
caused by homozygous NPHP1 full gene deletions (Levy and 
Feingold, 2000; Hildebrandt, 2010; Wolf & Hildebrandt, 2011). In 
iGeneTRAiN, we previously examined this region in a subset of 
iGeneTRAiN studies for adult-onset ESRD (n = 5,606 patients). 
Of the subjects analyzed, 26 patients showed homozygous NPHP1 
CNV deletions. Interestingly only 12% of these patients were 
previously diagnosed as having NPH and many presented with 
ESRD later in adulthood (Snoek et al., 2018). Thus, using the two 
copy gene loss of NPHP1 from GWG arrays to ascertain NPH 
status and examine NPH-related information in iGeneTRAiN 
studies, including accuracy of case-ascertainment and age-of-
onset, shows a strong proof-of-principle for use in other high 
penetrant autosomal recessive/dominant cases, and the need for 
further sequencing for rare single-nucleotide variants in adult-
onset ESRD patients. Furthermore, in a recent genome-wide 
analysis of CNVs in almost 3,000 cases of CAKUT, 45 distinct, 
known genomic disorders at 37 independent genomic loci were 
identified in 4% of CAKUT cases, and novel genomic disorders 
were found in an additional ~2% of cases (Verbitsky et al., 2019). 
Genome-wide genotyping and imputation using large whole-
genome sequencing (WGS) datasets, such as the 1000 genomes 
project (1KGP), typically cannot identify variants in the most 
common ancestral populations to a minor allele frequency 
(MAF) of <0.005, yet it is often possible to identify rare CNVs 
using monomorphic or SNP based probes across loci.
Our previous analyses of the Axiom TxArray genome-
wide genotyping data was primarily limited to approximately 
2,000 a priori CNV regions of interest that had specific probes 
designed onto the TxArray. Initial analyses used an adaption 
of the BRLMM-P CNV algorithm adapted from algorithms 
previously used to cluster genotypes across many samples 
(Yeung et al., 2008). However, BRLMM-P could only identify 
up to three clusters and thus was only able to detect 0, 1, and 
2 copy deletions. The newer Axiom Analysis Suite 4.0 software 
allows streamlined, targeted, and de-novo whole-genome CNV 
region analysis3. A major advantage of the newer software is the 
ability to detect duplications as well as 0, 1, and 2 copy deletions 
(Figure 2).
DISCUSSION
Genome-wide genotyping studies have become very affordable 
and streamlined. However, large sample sizes, on the order of 
10,000–100,000, are needed in order to detect both rare variants 
3 https://www.thermofisher.com
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TABLe 1 | Primary cause of ESRD in iGeneTRAiN kidney cohorts.
Primary 
Cause of 
eSRD
University of 
Pennsylvania
Transplant-
LINeS
BioMARGIN‡ Swiss 
Transplant 
Cohort 
Study†
WTCCC-
3†
Go-CAR Columbia 
Transplant 
Biobank
Torino 
Transplant 
Cohort‡
Rotterdam‡ DeKAF* Gen03* Scripps Leiden* vienna vanderbilt Seoul†, ‡
Diabetic 
nephropathy
310 (26.8%) 51 (4.0%) 115 (8.5%) 116 (7.4%) 186 
(7.3%)
219 
(37.2%)
176 
(15.6%)
22 (3.3%) – (17.0%) 553 
(28.5%)
178 
(22.8%)
– 22 
(25.0%)
113 
(12.8%)
– 240 
(20.9%)
Arteriopathic 
renal disease
202 (17.5%) 104 (8.2%) 67 (4.9%) 183 
(11.6%)
111 
(4.4%)
109 
(18.5%)
123 
(10.9%)
36 (5.4%) – (13.0%) 132 
(6.8%)
43 
(5.5%)
– – 88 
(10.0%)
– 244 
(21.3%)
Glomerular 
disease
340 (29.4%) 401 (31.6%) 329 (24.2%) 433 
(27.5%)
482 
(19.0%)
111 
(18.9%)
431 
(38.3%)
198 (29.7%) – (20.0%) 446 
(23.0%)
226 
(29.0%)
– 14 
(15.9%)
296 
(33.6%)
– 251 
(21.9%)
AKI 3 (0.3%) 1 (0.1%) 3 (0.2%) 0 (0.0%) 8 (0.3%) 0 (0.0%) 5 (0.4%) 2 (0.3%) – (4.0%) – – – – 4 (0.5%) – 0 (0.0%)
Infective and 
obstructive 
nephropathy
31 (2.7%) 107 (8.4%) 79 (5.8%) 85 (5.4%) 203 
(8.0%)
22 (3.7%) 17 (1.5%) 87 (13.1%) – (6.0%) – – – – 56 
(6.4%)
– 6 (0.5%)
Congenital 
diseases
19 (1.6%) 68 (5.4%) 57 (4.2%) 40 (2.5%) 26 (1.0%) 14 (2.4%) 58 (5.2%) 31 (4.7%) – (3.0%) – – – – 18 
(2.1%)
– 0 (0.0%)
Familial 
hereditary 
renal 
diseases
143 (12.4%) 235 (18.5%) 245 (18.0%) 327 
(20.8%)
361 
(14.2%)
67 
(11.4%)
145 
(12.9%)
110 (16.5%) – (14.0%) 308 
(15.9%)
123 
(15.8%)
– 52 
(59.1%)
147 
(16.7%)
– 25 
(2.2%)
Toxic 
nephropathy
2 (1.7%) 15 (1.2%) 19 (1.4%) 46 (2.9%) 16 (0.6%) 18 (3.1%) 31 (2.8%) 9 (1.4%) – (1.0%) – – – – 25 
(2.8%)
– 4 (0.4%)
Neoplasms 5 (0.4%) 6 (0.5%) 21 (1.5%) 0 (0.0%) 20 (0.8%) 2 (0.3%) 6 (0.5%) 5 (0.8%) – (3.0%) – – – – 14 
(1.6%)
– 0 (0.0%)
Other 
disease
50 (4.3%) 59 (4.6%) 64 (4.7%) 344 
(21.9%)
165 
(6.5%)
12 (2.0%) 9 (0.8%) 6 (0.9%) – (10.0%) 432 
(22.3%)
166 
(21.3%)
– – 17 
(1.9%)
– 0 (0.0%)
eSRD of 
unknown 
etiology
29 (2.5%) 168 (13.2%) 161 (11.8%) 0 (0.0%) 0 (0.0%) 14 (2.4%) 125 
(11.1%)
160 (24.0%) – (9.0%) – – – – 100 
(11.4%)
– 185 
(16.1%)
Missing 
information
4 (0.4%) 56 (4.4%) 200 (14.7%) 0 (0.0%) 966 
(38.0%)
0 (0.0%) 0 (0.0%) 0 (0.0%) – (0.0%) 67 
(3.5%)
44 
(5.6%)
– – 2 (0.2%) – 193 
(16.8%)
Total 1156 1271 1360 1574 2544 588 1126 666 – 1938 780 – 88 880 – 1148
*Data includes Caucasian only ancestry. ‡Recently added iGeneTRAiN kidney cohort.
†National level iGeneTRAiN kidney cohort. See Supplementary Table 1 for full breakdown of primary cause of ESRD.
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with large contributions and common variants with minor 
contributions to a specific phenotype(s) (Korte and Farlow, 
2013). While it is very important to bolster statistical power to 
detect genetic underpinnings of transplant-related phenotypes by 
aggregating similar cohorts, great caution must be exercised when 
combining genotyping and phenotyping datasets, especially as 
transplant study covariates are very complex and can vary greatly 
by era and geographical region. iGeneTRAiN does have a unified 
quality control/quality assurance GWAS pipeline, including 
adjustment for population-based stratification (International 
Genetics and Translational Research in Transplantation Network 
(iGeneTRAiN), 2015). Association study analyses do adjust 
for all known/available study covariates, including patient 
demographics and clinical characteristics, and we adjust for each 
FIGURe 2 | (A) Copy Number Variant Region Analyses of the NPHP1 locus using the Axiom Analysis Suite 4.0 to call diploid state (CN=2), one copy deletion state 
(CN=1), two copy deletion state (CN=0), and duplication state (CN=3). The x-axis shows the chromosomal location on Chromosome 2 while the y-axis shows the 
standard Log2Ratio intensity. (B) In depth illustration of the duplication (CN=3) state.
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transplant site alone to look for confounders. Genome-wide 
genotyping arrays are generally poor at detecting rarer frequency 
pathogenic variants, with the exception of medium to large 
CNVs. Significant advances in genomic technologies and the 
decreasing cost of WES/WGS efforts over the past several years 
have made it increasingly feasible to carry out better designed 
genome-wide studies in a clinical environment (Gumpinger 
et al., 2018). However, there are still significant advantages to 
having genome-wide genotyping array datasets, as rigorous 
quality control and quality assurance measures are generally 
performed on the original DNA, and gender, ancestry, and HLA 
(amino acid imputation) concordance checks can be performed 
before progressing to WES or WGS pipelines for deeper genetic 
characterization. GWAS are able to provide insight into genetic 
risk scores and pathogenic CNVs, as genome-wide variants 
are covered in conventional genome-wide genotyping arrays 
(Sampson and Juppner, 2013; Li et al., 2015 Marigorta et al., 
2018; Snoek et al., 2018; Stapleton et al., 2019). For example, a 
meta-analysis across 36 articles identified three genetic variants 
that are significantly associated with new onset diabetes after 
transplantation (NODAT), all of which are also known risk 
factor variants for Type 2 diabetes. The integration and analysis 
of large and complex multi-omic datasets has been demonstrated 
in a number of recent high impact publications, which in 
general increase, by approximately 10-fold, the statistical power 
to detect and illustrate functional variants (Chen et al., 2012; 
Piening et al., 2018; Schüssler-Fiorenza Rose et al., 2019; Zhou 
et al., 2019). iGeneTRAiN genomic data can be integrated with 
results from proteome-, metabolome-, and transcriptome-wide 
transplant studies to further characterize clinical risks and 
allow for personalized treatments, as a number of iGeneTRAiN 
studies have multi-omic datasets/samples (International 
Genetics and Translational Research in Transplantation Network 
(iGeneTRAiN), 2015).
The advent of single-cell RNA sequencing (scRNASeq) has 
yielded major insights into the biology of CKD. Expression 
quantitative trait loci (eQTL) atlases have been generated for 
glomerular and tubular compartments from human kidney 
cells. Integrating results from genome-wide studies of CKD with 
eQTL from scRNAseq as well as known regulatory region maps 
has been shown to identify novel CKD genes (Qiu et al., 2018). 
The Human Cell Atlas project is a major international initiative 
which aims to create comprehensive reference maps of all 
human cells to gain fundamental insight into the understanding 
of human health and will undoubtedly aid in the diagnoses and 
surveillance of a range of diseases (Regev et al., 2017).
Future of iGeneTRAiN  Kidney 
Cohorts Analyses
As the population of kidney transplant recipients and donors 
continues to grow in the iGeneTRAiN consortium and as 
post-transplant outcomes accrue, we will be able to further 
increase our knowledge of the genetic underpinnings of 
ESRD, primary disease, and post-transplant outcomes, such 
as acute rejection and graft loss. These sequencing approaches 
may provide additional insight into donor-recipient (D-R) 
interactions that influence graft outcomes. Although it is well 
established that allelic matches across HLA loci impact clinical 
outcomes post-transplant, there is a paucity of genome-wide 
research conducted to identify donor-recipient interactions 
independent of HLA (Thorsby, 2009; Chan-On and Sarwal, 
2016 ;Stapleton et al., 2018). One recent iGeneTRAiN kidney 
D-R study showed decreased allograft survival of recipients 
with increased D-R kidney transmembrane non-synonymous 
SNPs (nsSNPs). We further demonstrated that we could 
detect alloantibodies against customized amino-acid peptides 
designed with a number of these kidney transmembrane 
nsSNPs using sera from these patients (Reindl-Schwaighofer, 
et al., 2019). Finally, data from all solid-organ transplant 
studies in the iGeneTRAiN consortium will be utilized in 
cross-organ studies in order to gain additional insight into 
the genetics of acute rejection, allograft/patient survival, and 
pharmacogenomic outcomes.
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